Indoco Remedies Reports Q1 FY26 Results; Domestic Formulation Drives Growth Amid Strategic Focus
Indoco Remedies Limited has announced its Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The results reflect a focus on long-term strategy execution across core businesses despite a dynamic operating environment, with growth attributed primarily to the domestic formulation business.The company’s performance in the first quarter of the financial year 2026–27 saw revenues reach ₹4,081 million (mn) in the standalone segment, up from ₹3,856 mn in the same quarter last year. The Earnings Before Interest, Depreciation and Tax (EBITDA) to net sales for the quarter stood at 10.3%, compared to 3.8% in the previous year.
Standalone Financial Overview
The unaudited standalone financial results for the quarter ended June 30, 2026, showed significant figures across operational income and expenses. The company reported a gain of ₹9,734 lakhs from an exceptional item related to the slump sale of its Ophthalmic Business Division.Key metrics from the Standalone Financial Results are presented in the table below:
| Particulars | Quarter ended 30 June 2026 (Unaudited) | Quarter ended 31 March 2026 (Audited) | Quarter ended 30 June 2025 (Unaudited) |
|---|---|---|---|
| Revenue from Operations | 40,812 | 42,906 | 38,561 |
| Total Income (Net) | 447 | 1,035 | 558 |
| Total Expenses | 41,344 | 45,948 | 39,989 |
| Profit/Loss Before Exceptional Items and Tax | (412) | 2,394 | (2,841) |
| Profit for the period | 8,232 | 2,735 | (2,807) |
Geographic Segment Performance
The company's geographical breakdown of Net Sales and Income from Operations highlights its international sales strength alongside domestic operations.| Region | Quarter ended 30 June 2026 (Unaudited) | Quarter ended 31 March 2026 (Audited) | Quarter ended 30 June 2025 (Unaudited) |
|---|---|---|---|
| India | 22,775 | 19,363 | 22,255 |
| Outside India | 18,037 | 23,543 | 16,306 |
| Total | 40,812 | 42,906 | 38,561 |
Consolidated Financial Results
The consolidated financial results for the quarter ended June 30, 2026, reflect the combined performance of the Group and its subsidiaries.Key figures from the Consolidated Financial Results are as follows:
| Particulars | Quarter ended 30 June 2026 (Unaudited) | Quarter ended 31 March 2026 (Audited) | Quarter ended 30 June 2025 (Unaudited) |
|---|---|---|---|
| Revenue from Operations | 6,622 | 45,590 | 43,086 |
| Total Income from Operations (Net) | 46,750 | 47,561 | 43,967 |
| Total Expenses | 46,968 | 47,557 | 44,130 |
| Profit for the period | 6,544 | (2,368) | 13,635 |
Management Commentary and Audit Opinion
Ms. Aditi Panandikar, Managing Director of Indoco Remedies Ltd., stated that the results reflect the continued execution of the company's long-term strategy. She attributed the growth to the resilient Domestic Formulation business while noting that international formulations and API businesses continued making steady progress.The unaudited standalone and consolidated financial results were reviewed by the Audit Committee, and the Statutory Auditors issued a Limited Review Report with an unmodified opinion on these results for the quarter ended June 30, 2026.
INDOCO Stock Price Movement
As of 1:00 PM, shares of Indoco Remedies Limited are slipping by 2.13% in live trading after shedding ₹5.29, currently seeing the stock trade at ₹242.85. The stock has seen brisk activity so far today, with 3.38 million shares changing hands.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.